



## Albireo to Participate in Upcoming Investor Conferences

September 3, 2019

BOSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Simon Harford, Chief Financial Officer, will present at the 21<sup>st</sup> Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, in New York City on Monday, September 9, 2019, at 10 a.m. EDT.

A live audio webcast of the presentation will be accessible from the Media & Investors page of Albireo's website, [ir.albireopharma.com](http://ir.albireopharma.com). To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay in the Events & Presentations section of the Media & Investors page of Albireo's website for at least two weeks following the event.

The company will also participate in the Ladenburg Thalmann 2019 Healthcare Conference in New York City on September 24, 2019.

### About Albireo

Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis (PFIC). Albireo's clinical pipeline also includes two Phase 2 product candidates. Elobixibat is in Phase 2 development in NAFLD and NASH. Approved in Japan for the treatment of chronic constipation, elobixibat is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world.

Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Mass., and its key operating subsidiary is located in Gothenburg, Sweden. The *Boston Business Journal* named Albireo one of the 2019 Best Places to Work in Massachusetts. For more information on Albireo, please visit [www.albireopharma.com](http://www.albireopharma.com).

**Investor Contact:** Hans Vitzthum, LifeSci Advisors, LLC, 212-915-2568

**Media Contact:** Heather Anderson, 6 Degrees, 980-938-0260, [handerson@6degreespr.com](mailto:handerson@6degreespr.com)

Source: Albireo Pharma, Inc.



Source: Albireo Pharma, Inc.